Sarepta Therapeutics Inc $21.00

down -0.34


1/8/2014 11:00 AM  |  NASDAQ : SRPT  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get SRPT Trend Analysis - it has underperformed the S&P 500 by 57%

Partner Headlines

  1. Stocks Mixed Despite Better-Than-Expected GDP

    Benzinga
  2. Sarepta Up 12% As FDA Is 'Actively Engaged' On Drug Application

    Benzinga
  3. Morning Market Losers

    Benzinga
  4. Benzinga's Top #PreMarket Losers

    Benzinga
  5. Shares of Sarepta Therapeutics Plummet on CSO Termination

    Benzinga
  6. Mid-Afternoon Market Movers For July 10, 2014

    Benzinga
  7. Deutsche Bank Questions Long-Term Efficacy Of Sarepta's Eteplirsen Following ...

    Benzinga
  8. Lumber Liquidators Falls On Weak Forecast; Zumiez Shares Spike Higher

    Benzinga
  9. Markets Open Lower; Family Dollar Profit Misses Estimates

    Benzinga
  10. Morning Market Losers

    Benzinga
  11. UPDATE: Sarepta Therapeutics Announces $100M Proposed Public Offering of ...

    Benzinga
  12. Five Star Stock Watch: Sarepta Therapeutics

    Benzinga
  13. Benzinga's Top Upgrades

    Benzinga
  14. Mid-Afternoon Market Update: Markets Remain in the Green as Moneygram Falls ...

    Benzinga
  15. Sarepta Revives Hopes For Muscular Dystrophy Drug

    IBD
  16. Mid-Day Market Update: AMD Surges After Upbeat Results; Acacia Research ...

    Benzinga
  17. Benzinga's Volume Movers

    Benzinga
  18. Mid-Morning Market Update: Markets Rise; Halliburton Posts Q1 Profit

    Benzinga
  19. Morning Market Movers

    Benzinga
  20. Stock Futures Defend Thin Gains; Halliburton And Revlon Climb

    IBD
  21. Benzinga's Top #PreMarket Gainers

    Benzinga
  22. Barron's Recap: Sunny Skies For Home Depot

    Benzinga
  23. Prosensa Muscular Dystrophy Data Send Stock Rising

    IBD
  24. Benzinga's Top #PreMarket Losers

    Benzinga
  25. UPDATE: Sarepta Announces Positive Safety Results from Phase I Trial of ...

    Benzinga
  26. UPDATE: JMP Downgrades Sarepta, Data Considered Weak and Overstated

    Benzinga
  27. Needham Upgrades Sarepta, Says Stock Underalued Even In Conservative Case

    Benzinga
  28. Is The Market On Drugs?

    Benzinga
  29. Mid-Morning Market Update: Markets Mostly Lower; Goldman Sachs Posts Upbeat ...

    Benzinga
  30. Morning Market Movers

    Benzinga
  31. Benzinga's Top #PreMarket Gainers

    Benzinga
  32. UPDATE: Sarepta Downgraded by Citigroup on Eteplirsen Early Approval Setback

    Benzinga
  33. Mid-Morning Market Update: Markets Mostly Lower; GE To Acquire Thermo Fisher ...

    Benzinga
  34. Morning Market Losers

    Benzinga
  35. Benzinga's Top #PreMarket Losers

    Benzinga
  36. UPDATE: Canaccord Genuity Downgrades Sarepta Therapeutics as FDA Talks ...

    Benzinga
  37. Market Wrap For November 26: Nasdaq Closes Above 4,000 For First Time Since ...

    Benzinga
  38. Mid-Afternoon Market Update: Markets Rise as NASDAQ Eyes Close Over 4, ...

    Benzinga
  39. UPDATE: Deutsche Bank Downgrades Sarepta Therapeutics Following FDA Announcement ...

    Benzinga
  40. Sarepta Plunges And Love Affair Ends (For Now)

    YCharts
  41. Sarepta sinks on FDA report

    IBD
  42. Market Wrap For November 12: Investors Continue to Speculate on the Fed's ...

    Benzinga
  43. Mid-Afternoon Market Update: Markets in the Red as American Airlines/US ...

    Benzinga
  44. Sarepta Therapeutics Plunges On Negative FDA Report

    IBD
  45. UPDATE: Piper Jaffray Downgrades Sarepta Therapeutics After FDA Reverses ...

    Benzinga
  46. Benzinga's Top #PreMarket Losers

    Benzinga
  47. Sarepta Therapeutics Announces FDA Considers NDA Filing for Eteplirsen ...

    Benzinga
  48. PPMD, Sarepta Report Program for Genetic Testing at No Cost

    Benzinga
  49. Insiders Are Buying Fate Therapeutics

    GuruFocus
  50. Sarepta Takes The Lead In Muscular Dystrophy Race

    IBD
Trading Center